NASDAQ: PRPHProphase Labs Inc Stock
$0.29+0.01 (+3.57%)
Updated Apr 17, 2025
PRPH Price
$0.29
Fair Value Price
N/A
Market Cap
$12.06M
52 Week Low
$0.22
52 Week High
$5.62
P/E
-0.11x
P/B
1.64x
P/S
2.29x
PEG
N/A
Dividend Yield
N/A
Revenue
$6.77M
Earnings
-$53.36M
Gross Margin
-2.2%
Operating Margin
-632.48%
Profit Margin
-788.2%
Debt to Equity
7.6
Operating Cash Flow
-$18M
Beta
0.81
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
PRPH Overview
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PRPH's potential to beat the market
- PRPH doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
B
PRPH
RankedUnranked of 45
RankedUnranked of 45
Be the first to know about important PRPH news, forecast changes, insider trades & much more!
PRPH News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PRPH scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PRPH is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PRPH is good value based on its book value relative to its share price (1.64x), compared to the US Diagnostics & Research industry average (3.26x)
P/B vs Industry Valuation
PRPH is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 35 more PRPH due diligence checks available for Premium users.
Valuation
PRPH fair value
Fair Value of PRPH stock based on Discounted Cash Flow (DCF)
Price
$0.29
Fair Value
-$0.31
Undervalued by
193.94%
PRPH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PRPH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.11x
Industry
36.04x
Market
27.98x
PRPH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.64x
Industry
3.26x
PRPH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PRPH's financial health
Profit margin
Revenue
-$2.5M
Net Income
-$34.4M
Profit Margin
1,383.2%
PRPH's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PRPH's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$63.2M
Liabilities
$55.8M
Debt to equity
7.6
PRPH's short-term liabilities ($32.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PRPH's short-term assets ($30.64M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PRPH's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PRPH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.6M
Investing
-$40.0k
Financing
$3.7M
PRPH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PRPH vs Diagnostic & Research Stocks
Prophase Labs Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.